MX385960B - Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). - Google Patents
Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd).Info
- Publication number
- MX385960B MX385960B MX2017009540A MX2017009540A MX385960B MX 385960 B MX385960 B MX 385960B MX 2017009540 A MX2017009540 A MX 2017009540A MX 2017009540 A MX2017009540 A MX 2017009540A MX 385960 B MX385960 B MX 385960B
- Authority
- MX
- Mexico
- Prior art keywords
- dcm
- treatment
- dilated cardiomyopathy
- substituted piperidine
- methylsulfonyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona nuevos compuestos de piperidina urea 4-metilsulfona-sustituidos que son útiles para el tratamiento de miocardiopatía dilatada (MCD) y afecciones asociadas a disfunción sistólica o reserva sistólica ventricular izquierda y/o derecha. Se describen la síntesis y la caracterización de los compuestos, así como métodos para tratar MCD y otras formas de enfermedad cardíaca.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106571P | 2015-01-22 | 2015-01-22 | |
| PCT/US2016/014365 WO2016118774A1 (en) | 2015-01-22 | 2016-01-21 | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009540A MX2017009540A (es) | 2017-10-20 |
| MX385960B true MX385960B (es) | 2025-03-18 |
Family
ID=55275230
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007040A MX2022007040A (es) | 2015-01-22 | 2016-01-21 | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). |
| MX2021010778A MX394704B (es) | 2015-01-22 | 2016-01-21 | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) |
| MX2017009540A MX385960B (es) | 2015-01-22 | 2016-01-21 | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007040A MX2022007040A (es) | 2015-01-22 | 2016-01-21 | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). |
| MX2021010778A MX394704B (es) | 2015-01-22 | 2016-01-21 | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9925177B2 (es) |
| EP (2) | EP4234017A3 (es) |
| JP (1) | JP6712275B2 (es) |
| KR (3) | KR102585550B1 (es) |
| CN (3) | CN118164961A (es) |
| AU (4) | AU2016209200B2 (es) |
| BR (1) | BR112017015627B1 (es) |
| CA (1) | CA2974370C (es) |
| CL (1) | CL2017001871A1 (es) |
| CO (1) | CO2017008398A2 (es) |
| CR (1) | CR20170370A (es) |
| DK (1) | DK3247707T3 (es) |
| DO (2) | DOP2017000166A (es) |
| EA (1) | EA036923B1 (es) |
| EC (1) | ECSP17054181A (es) |
| ES (1) | ES2953480T3 (es) |
| FI (1) | FI3247707T3 (es) |
| GT (1) | GT201700163A (es) |
| HR (1) | HRP20230737T1 (es) |
| HU (1) | HUE063410T2 (es) |
| IL (6) | IL313678A (es) |
| LT (1) | LT3247707T (es) |
| MX (3) | MX2022007040A (es) |
| MY (1) | MY203427A (es) |
| PE (2) | PE20212253A1 (es) |
| PH (2) | PH12017501279B1 (es) |
| PL (1) | PL3247707T3 (es) |
| PT (1) | PT3247707T (es) |
| RS (1) | RS64432B1 (es) |
| SG (2) | SG10201913047UA (es) |
| SI (1) | SI3247707T1 (es) |
| SM (1) | SMT202300259T1 (es) |
| TN (1) | TN2017000320A1 (es) |
| UA (1) | UA119905C2 (es) |
| WO (1) | WO2016118774A1 (es) |
| ZA (1) | ZA201704777B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10758525B2 (en) | 2015-01-22 | 2020-09-01 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds |
| EA202090688A1 (ru) | 2017-09-13 | 2020-07-06 | Эмджен Инк. | Бис-амидные соединения, активирующие саркомер, и варианты их применения |
| MD3740481T3 (ro) | 2018-01-19 | 2025-06-30 | Cytokinetics Inc | Analogi de dihidrobenzofuran și inden în calitate de inhibitori ai sarcomerului cardiac |
| SG11202007328UA (en) | 2018-02-01 | 2020-08-28 | Myokardia Inc | Pyrazole compounds and preparation thereof |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| GB201813312D0 (en) | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| CA3110237A1 (en) | 2018-08-31 | 2020-03-05 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| GB201905520D0 (en) | 2019-04-18 | 2019-06-05 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| PE20220426A1 (es) * | 2019-05-19 | 2022-03-29 | Myokardia Inc | Tratamiento de la disfuncion sistolica e insuficiencia cardiaca con fraccion de eyeccion reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida |
| EP3999504A1 (en) * | 2019-07-16 | 2022-05-25 | MyoKardia, Inc. | Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| MX2022013657A (es) | 2020-05-05 | 2023-02-01 | Nuvalent Inc | Quimioterápicos de éter macrocíclico heteroaromático. |
| EP4146205A4 (en) | 2020-05-05 | 2024-05-29 | Nuvalent, Inc. | HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS |
| BR112022025551A2 (pt) * | 2020-06-15 | 2023-03-07 | Myokardia Inc | Tratamento de disfunção atrial |
| KR102541297B1 (ko) | 2020-08-18 | 2023-06-09 | 가톨릭대학교 산학협력단 | 확장성 심근병 모델 및 이의 제조방법 |
| JP2024508526A (ja) | 2021-03-04 | 2024-02-27 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| CA3231813A1 (en) | 2021-10-01 | 2023-04-06 | Sibao CHEN | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds |
| CN116082326B (zh) * | 2022-12-16 | 2024-12-27 | 药康众拓(江苏)医药科技有限公司北京分公司 | 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途 |
| WO2025244956A1 (en) | 2024-05-20 | 2025-11-27 | MyoKardia, Inc. | Methods of manufacturing danicamtiv |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117882A2 (en) * | 2004-04-20 | 2005-12-15 | Incyte Corporation | Hydroxamic acid derivatives as metalloprotease inhibitors |
| MXPA06014495A (es) * | 2004-06-17 | 2007-03-01 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| US8324178B2 (en) * | 2008-10-31 | 2012-12-04 | The Regents Of The University Of California | Method of treatment using alpha-1-adrenergic agonist compounds |
| WO2010068452A1 (en) * | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| CA2778175A1 (en) * | 2009-11-11 | 2011-05-19 | Yoshihiro Horiuchi | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative |
-
2016
- 2016-01-21 KR KR1020177022900A patent/KR102585550B1/ko active Active
- 2016-01-21 FI FIEP16702652.5T patent/FI3247707T3/fi active
- 2016-01-21 LT LTEPPCT/US2016/014365T patent/LT3247707T/lt unknown
- 2016-01-21 IL IL313678A patent/IL313678A/en unknown
- 2016-01-21 AU AU2016209200A patent/AU2016209200B2/en active Active
- 2016-01-21 DK DK16702652.5T patent/DK3247707T3/da active
- 2016-01-21 CN CN202410163448.9A patent/CN118164961A/zh active Pending
- 2016-01-21 UA UAA201708527A patent/UA119905C2/uk unknown
- 2016-01-21 BR BR112017015627-0A patent/BR112017015627B1/pt active IP Right Grant
- 2016-01-21 EP EP23170487.5A patent/EP4234017A3/en active Pending
- 2016-01-21 SG SG10201913047UA patent/SG10201913047UA/en unknown
- 2016-01-21 MY MYPI2017702553A patent/MY203427A/en unknown
- 2016-01-21 SI SI201631723T patent/SI3247707T1/sl unknown
- 2016-01-21 RS RS20230542A patent/RS64432B1/sr unknown
- 2016-01-21 PT PT167026525T patent/PT3247707T/pt unknown
- 2016-01-21 JP JP2017538593A patent/JP6712275B2/ja active Active
- 2016-01-21 PH PH1/2017/501279A patent/PH12017501279B1/en unknown
- 2016-01-21 SM SM20230259T patent/SMT202300259T1/it unknown
- 2016-01-21 PE PE2021001384A patent/PE20212253A1/es unknown
- 2016-01-21 HU HUE16702652A patent/HUE063410T2/hu unknown
- 2016-01-21 HR HRP20230737TT patent/HRP20230737T1/hr unknown
- 2016-01-21 SG SG11201705928XA patent/SG11201705928XA/en unknown
- 2016-01-21 PL PL16702652.5T patent/PL3247707T3/pl unknown
- 2016-01-21 MX MX2022007040A patent/MX2022007040A/es unknown
- 2016-01-21 CR CR20170370A patent/CR20170370A/es unknown
- 2016-01-21 IL IL295547A patent/IL295547A/en unknown
- 2016-01-21 KR KR1020237033324A patent/KR102688851B1/ko active Active
- 2016-01-21 PE PE2017001241A patent/PE20171511A1/es unknown
- 2016-01-21 PH PH1/2021/553074A patent/PH12021553074A1/en unknown
- 2016-01-21 CA CA2974370A patent/CA2974370C/en active Active
- 2016-01-21 TN TNP/2017/000320A patent/TN2017000320A1/en unknown
- 2016-01-21 US US15/003,662 patent/US9925177B2/en active Active
- 2016-01-21 CN CN202010152637.8A patent/CN111393414B/zh active Active
- 2016-01-21 ES ES16702652T patent/ES2953480T3/es active Active
- 2016-01-21 KR KR1020247024828A patent/KR20240119163A/ko active Pending
- 2016-01-21 MX MX2021010778A patent/MX394704B/es unknown
- 2016-01-21 EA EA201791656A patent/EA036923B1/ru not_active IP Right Cessation
- 2016-01-21 EP EP16702652.5A patent/EP3247707B1/en active Active
- 2016-01-21 CN CN201680017126.7A patent/CN107428719B/zh active Active
- 2016-01-21 MX MX2017009540A patent/MX385960B/es unknown
- 2016-01-21 WO PCT/US2016/014365 patent/WO2016118774A1/en not_active Ceased
-
2017
- 2017-07-14 ZA ZA2017/04777A patent/ZA201704777B/en unknown
- 2017-07-18 IL IL253552A patent/IL253552B/en active IP Right Grant
- 2017-07-19 DO DO2017000166A patent/DOP2017000166A/es unknown
- 2017-07-20 GT GT201700163A patent/GT201700163A/es unknown
- 2017-07-20 CL CL2017001871A patent/CL2017001871A1/es unknown
- 2017-08-17 CO CONC2017/0008398A patent/CO2017008398A2/es unknown
- 2017-08-21 EC ECIEPI201754181A patent/ECSP17054181A/es unknown
-
2019
- 2019-11-28 IL IL271034A patent/IL271034A/en active IP Right Grant
-
2020
- 2020-09-30 AU AU2020244490A patent/AU2020244490B2/en active Active
- 2020-12-06 IL IL279247A patent/IL279247A/en unknown
-
2021
- 2021-09-13 IL IL286369A patent/IL286369A/en unknown
-
2022
- 2022-08-24 DO DO2022000172A patent/DOP2022000172A/es unknown
-
2023
- 2023-01-24 AU AU2023200361A patent/AU2023200361B2/en active Active
-
2024
- 2024-11-21 AU AU2024266781A patent/AU2024266781A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385960B (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). | |
| MX2015017865A (es) | Compuestos de pirimidinodiona contra estados cardiacos. | |
| SA519401435B1 (ar) | مركبات حلقية ثنائية النيوكليوتيد | |
| EA202090720A1 (ru) | ПРОИЗВОДНЫЕ GalNAc | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| EA201691913A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| MX2024004892A (es) | Compuestos de pirimidinodiona biciclica sustituidos con tetrahidropirano (thp). | |
| EA201890442A1 (ru) | Получение фоторецепторов для лечения заболеваний сетчатки | |
| EA201692289A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| EA202190045A1 (ru) | Составы/композиции, содержащие ибрутиниб | |
| EA201692371A1 (ru) | 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений | |
| EA201791745A1 (ru) | Производные тетрагидропиранилбензамида | |
| NZ772098A (en) | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) | |
| EA201791388A1 (ru) | Общий синтез триоксакарцина dc-45-a2 и получение аналогов триоксакарцина | |
| EA202090336A1 (ru) | Соединения, их соли и способы лечения заболеваний |